Takeda offloads yet more “non-core” assets with other deals likely to follow
The Japanese big pharma continues to divest drug rights to pay down its debt and fund desperately needed innovation
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10